PARTI Overview We are a vertically integrated, clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including radiation-induced xerostomia, Parkinsons disease and AIPL1-associated retinal dystrophy. Our clinical programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need. The successful development of the clinical pipeline is supported by our internal end-to-end manuf...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001104659-26-036494 | EDGAR | 121K words |
| 2025-03-13 | 2024-12-31 | 0001558370-25-002867 | EDGAR | — |
| 2024-03-15 | 2023-12-31 | 0001558370-24-003309 | EDGAR | — |
| 2023-03-14 | 2022-12-31 | 0001558370-23-003674 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001558370-22-003302 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001558370-21-002773 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001558370-20-002429 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001193125-19-086735 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001104659-25-110898 | EDGAR | 74K words |
| 2025-08-14 | 2025-06-30 | 0001558370-25-011512 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001558370-25-007498 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001558370-24-015444 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001558370-24-011788 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001558370-24-007477 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001558370-23-018916 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001558370-23-014416 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001558370-23-009274 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001558370-22-017417 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001558370-22-013192 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001558370-22-008452 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001104659-26-034904 | EDGAR | 5K words |
| 2026-01-02 | 0001104659-26-000068 | EDGAR | — |
| 2025-11-13 | 0001104659-25-110883 | EDGAR | — |
| 2025-11-10 | 0001104659-25-108804 | EDGAR | — |
| 2025-08-14 | 0001558370-25-011478 | EDGAR | — |
| 2025-06-26 | 0001558370-25-008870 | EDGAR | — |
| 2025-06-17 | 0001558370-25-008676 | EDGAR | — |
| 2025-05-13 | 0001558370-25-007497 | EDGAR | — |
| 2025-05-09 | 0001558370-25-007074 | EDGAR | — |
| 2025-04-04 | 0001558370-25-004490 | EDGAR | — |
129 total filings indexed. 99 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001735438 |
| Ticker | MGTX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.meiragtx.com |
| Listed | 2018-06-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report